Hefty cuts to government funding of blood tests and x-rays sparked a sell-off in healthcare stocks and drew sharp criticism from the doctors' lobby.
On Tuesday the federal government's Mid-Year Economic and Fiscal Outlook (MYEFO) identified $650.4 million of savings over the next four years, from reducing or removing bulk-billing incentive payments for certain pathology and imaging tests.
Loading...
Tim Binsted writes on Business specialising in Agriculture, Construction, Manufacturing. Tim is based in our Sydney newsroom. Connect with Tim on Twitter.
